Prosight Management LP lessened its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 12.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,500,000 shares of the company's stock after selling 221,512 shares during the period. Roivant Sciences makes up approximately 4.9% of Prosight Management LP's portfolio, making the stock its 9th largest position. Prosight Management LP owned 0.21% of Roivant Sciences worth $17,745,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Treasurer of the State of North Carolina raised its stake in Roivant Sciences by 0.6% during the 4th quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company's stock valued at $2,213,000 after acquiring an additional 1,170 shares during the last quarter. WINTON GROUP Ltd lifted its position in shares of Roivant Sciences by 1.5% in the fourth quarter. WINTON GROUP Ltd now owns 92,526 shares of the company's stock valued at $1,095,000 after acquiring an additional 1,332 shares in the last quarter. Covestor Ltd lifted its holdings in Roivant Sciences by 7.5% in the 4th quarter. Covestor Ltd now owns 20,634 shares of the company's stock valued at $245,000 after purchasing an additional 1,444 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after buying an additional 1,507 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Roivant Sciences by 6.1% in the fourth quarter. Victory Capital Management Inc. now owns 27,494 shares of the company's stock valued at $325,000 after buying an additional 1,588 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Roivant Sciences
In related news, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the completion of the transaction, the chief operating officer now owns 896,869 shares in the company, valued at $9,551,654.85. This trade represents a 10.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the business's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the completion of the sale, the insider now owns 39,799,611 shares in the company, valued at $456,501,538.17. This represents a 0.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,223,959 shares of company stock worth $13,420,035 in the last 90 days. 7.90% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
ROIV has been the topic of several analyst reports. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Monday, April 21st.
Check Out Our Latest Stock Report on ROIV
Roivant Sciences Stock Up 0.4%
Shares of NASDAQ:ROIV traded up $0.05 during trading on Tuesday, reaching $10.89. The stock had a trading volume of 1,086,385 shares, compared to its average volume of 5,769,134. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The stock has a fifty day simple moving average of $10.51 and a two-hundred day simple moving average of $11.07. The firm has a market capitalization of $7.77 billion, a price-to-earnings ratio of -72.56 and a beta of 1.23.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
